DNA topoisomerase I is a nuclear enzyme which catalyzes the conversion of the DNA topology by introducing single-strand breaks into the DNA molecule. This enzyme represents a novel and distinct molecule target for cancer therapy by antitopoisomerase drugs belonging to the campthotecin series of antineoplastics. As many tumors can acquire resistance to drug treatment and become refractary to the chemotherapy it is very important to investigate the mechanisms involved in such a drug resistance for circumventing the phenomenon.
Introduction
The success of anticancer chemotherapy is basically due to a cytotoxic mechanism in combination with a selective capacity of the drug to distinguish tumor cells from normal host cells. Thus, resistance to drug toxicity in tumor cells is the major problem for succesful cancer treatment because it eliminates therapeutic selectivity.
Generally, metastatic cancers are intrinsically resistant to drug treatment or, in spite of a first promising response, can acquire resistance to multiple drugs (Multiple Drug Resistance) and become refractory at time of relapse or progression. Therefore, it is very important to know the mechanisms involved in drug resistance in order to attempt to circumvent the phenomenon and make the therapy more effective.
Among the cytotoxic drugs currently used in cancer chemotherapy the chemicals which inhibit DNA topoisomerases have a relevant role both for their wide use and for their important implication in the phenomena of resistance. Recently, topoisomerase I inhibitors have received approval for the treatment of human cancers. Hycamtin TM is an oncology product containing topotecan, whereas Cytosar TM is the formulated product of CPT-11. In fact, the function of Topoisomerases is to modulate the topology of DNA by complex processes of strand cleavage, passage and following religation. They have an important function in chromosome condensation and segregation other than transposition, recombination, replication, transcription and DNA repair processes (Vinograd et al., 1965; Liu, 1983; Kafiani et al., 1986; Zijlstra et al., 1990; Hsiang et al., 1992; Cobb et al., 1997) and for this reason the topoisomerase inhibitors play a decisive role in controlling cell proliferation.
Two types of topoisomerases (Topo I and Topo II) have been distinguished and characterized. Topoisomerase I catalyzes the conversion of the DNA topology by introducing single-strand breaks into the DNA molecule. Topoisomerase II (two mammalian isoforms have been purified: II-alpha of p170 kDa and IIbeta of p180 kDa) are able to cleave double-stranded DNA and can support more complex interconversions of the DNA topology by an ATP-dependent strand passage process (Wang, 1985; D'Arpa, 1989) . This paper considers only the function of eukaryotic Topoisomerase I and describes the mechanism of Topoisomerase I inhibitors by discussing the possible ways by which tumoral cells may become resistant to these drugs.
A particular attention is given to the known mechanisms of multi-drug resistance, the 'in vitro' systems developed for assaying Topoisomerase I activity, and the methods for assessing and investigating drug resistance of primary and established tumor cell lines to topoisomerase I poisons.
Mechanism of Action of Topoisomerase I
Human DNA topoisomerase I is a monomeric protein of 100 kDa (Gellert, 1981) encoded by a single copy gene located on chromosome 20q12-13.2 (Juan et al., 1988; Zhou et al., 1989) . Eukaryotic DNA topoisomerase I catalizes the relaxation of positively and negatively supercoiled DNA acting as a swivel for removing torsional strains from DNA helix. It nicks one DNA strand (cleavage step) and then reseals the break (religation step) after a single rotation event.
The whole process is an ATP-independent mechanism which does not require Mg 2+ (the reaction is stimulated by Mg 2+ ions and other polycations while it is inhibited by polyanions).
DNA topoisomerase I binds preferentially at the nodes created by the crossing of two duplex elices (Madden et al., 1995) and is assumed to form two different complexes with DNA: a non-cleavable complex and a cleavable complex. The cleavable complex represents a transient covalent intermediate formed by DNA-topoisomerase I which induces a single strand nick. The covalent linking of Topo I to the 3 -phosphoryl end of the broken DNA strand is made possible by the presence of a tyrosine (Champoux, 1981) . The consequence of this break is the rotation of the two broken ends of DNA leading to relaxation of the supercoiled DNA. If this complex is treated with a strong protein denaturant (such as Sodium Dodecyl Sulphate or alkali) a protein-linked single strand DNA break is produced (See Figure 1) . Also many drugs (as topoisomerase I inhibitors) can stabilize this DNA-Topo I complex.
The enzyme is present in the nucleolous and nucleoplasm of cells (Muller et al., 1985) and the content doubles as the cells progress from G1 to G2/M phases of the cell cycle remaining almost constant when the cells are normalized for nuclear size (Baker et al., 1995) .
As evidenced by many studies, several leukemias and lymphomas (Potmesil et al., 1988) , colon adenocarcinomas (Giovannella et al., 1989; Husain, 1994) as well as many different types of human malignancies (Masin et al., 1995; Bronstein et al., 1996; McLeod et al., 1994) express higher levels of topoisomerase I than normal tissues.
The role of topoisomerase I has not been completely clarified even for the multiplicity of biochemical functions described. It seems to be very important in the transcription processes Liu LF, 1989) by promoting both the separation of the two DNA strands (for receiving the RNA-polymerase complex) and the subsequent rapid rotation of DNA (that allows copying of the base sequence into the newly formed RNA strand) (Rose et al., 1988) . As suggested by Wang (1996) the topoisomerase system (type I and II) may also prevent excessive supercoiling of DNA generated by a number of processes involving the movement of macromolecular assemblies along DNA, and human topoisomerase I is probably a part of a nucleoprotein complex structure which is involved in the regulation of many genes. Recently Topo I has been identified as specific kinase for phorphorylation of SR protein splicing factors and futhermore there are evidences that it can form molecular complexes with p53 both 'in vitro' and 'in vivo' suggesting that p53 mediated response to DNA damage may, at least in part, involve activation of topo I (Gobert et al., 1996) . Topoisomerase I appears to be essential also for the genomic insertion of viral DNA (Wang et al., 1991) and its activity is enhanced by phosphorylation and is inactivated by poly-ADPribosylation (Pommier, 1990; Turman, 1993) A list of the most important functions attributed to the eukaryotic DNA topoisomerase I is reported in Table I . For a complete review on topoisomerases see Wang, 1996 .
In Vitro Assay of Topoisomerase I Activity
Many methods have been developed for quantifying topoisomerase I activity. One strategy is based on the measurement of the damage produced by the enzyme on the DNA molecules after incubation of whole cells or nuclei in the presence of drugs able to stabilize the cleavable complex. These methods are based on the alkaline and neutral elution assay (Khon et al., 1981) that measure strand breaks in DNA as DNA- Figure 1 . Schematic representation of Topo I mechanism. Exposure of the cleavable complex (in equilibrium with non-cleavable) to strong protein denaturant produces a single strand DNA breaks linked to topoisomerase I. After digestion of the topo I with proteinaseK the relative quantity of supercoiled and relaxed DNA may be assessed by agarose gel electrophoresis.
DNA cross links by means of radiolabeled thymidine or by detecting differences in the fluorescence of DNA (Kanter and Schwartz, 1982) . By similar techniques (as SDS sedimentation or filter binding assay) DNAbound protein can also be measured, assuming that the majority of the linked protein is topoisomerase (Trask et al., 1984; Liu et al., 1983) . All these systems give quantitative but non-specific data owing to the indirect nature of the measurement.
A second group is represented by more specific assays which measure the direct 'in vitro' relaxing activity of topoisomerase I on supercoiled DNA as substrate (e.g.: pBR322, ColE1, pUC18, PC15, pAO3, OX174) . This tests, first described by Wang 1971 , measures the catalytic activity of Topo I in the absence of ATP and Mg 2+ by detecting the nicked intermediate complex after protein denaturation with SDS. Following digestion by proteinase K, the relaxed product (nicked open circular DNA) may be quantified on agarose gel electrophoresis by ethidium bromide staining. The test works well also with crude nuclear extract and supercoiled substrate. This relaxation test has been widely used to study specific 'in vitro' effect of drugs and chemical on topoisomerase I either for evaluating the capacity of a compound to stabilize the nicked intermediate or to inhibit catalytic activity of topoisomerase I (Hussy et al., 1986) .
Another technique is based on the detection of the enzyme by means of specific anti-topo I antibodies directly performed on whole cells (immunocytochemistry) or by Western blot analysis of the nuclear extract This type of assays is highly specific but does not seems to be predictive of the biological activity of the enzyme (Tsuruo et al., 1988) .
A quantitative polymerase chain reaction (PCR) method to determine DNA topoisomerase I in cell lines and tumor samples has been developed and reported by Yang et al., 1993 . For a detailed review concerning 'in vitro' assays used to measure the activity of topoisomerases see Barrett et al., 1990 . Many of these powerful new technologies are available commercially as an assay kit by Topogen inc. (Ohio, U.S.A.).
Topoisomerase I Inhibitors
Intercalator drugs of the acridine group (Pommier, 1985) , actynomycin-D (Trask et al., 1988) distamycin (Smith, 1990) and also heparin have evidenced the capacity to inhibit in vitro the topoisomerase I activity present in nuclear extract . Recently Chen et al. (1993) pointed out the capacity of Hoechst dye 33342 to interrupt the breakage/reunion reac- The most specific drug family of topoisomerase I inhibitors is the camptothecin series (Figure 2 ), named for the prototype natural product camptothecin, a plant alkaloid isolated from Camptotheca acuminata that was developed as an antitumor drug (Wall et al., 1966; see Horwitz, 1975) . In recent studies it has been identified as a specific topoisomerase I inhibitor. In fact, by studying the products of topo I cleavable complexes it has been proved that the protein linked to broken DNA in detergent lysates of camptothecin treated cells was topo I (Hsiang, 1985; .
Camptothecin is a lactone that equilibrates with the opened-ring carboxylate form under physiological conditions. Because of its greater solubility, the sodium salt of camptothecin carboxylate was the first of the series to be evaluated clinically. However, clinical development was halted because of life-threatening myelosuppression, diarrhea, and hemorraghic cystitis (Gottlieb et al., 1970; Muggia et al., 1972) .
Clinical interest in the camptothecin series was renewed based on findings that the lactone form is the active species and is less toxic to the urinary system (Slichenmyer et al., 1993) . Formulation of camptothecins have been improved by the development of second generation analogs with greater water solubility such as the lactone forms of topotecan (9-(dimethylamino)methyl-10-hydroxycamptothecin) and Irinotecan (7-thyl-10-(4-(1-pi- peridino)-1-piperidino)carbonyloxycamptothecin). The products based on these camptothecins, Hycamtin TM and Camptosar TM , have been approved for oncology indications in the United States and Japan.
In Europe the procedure (concerning Campto-R) is ongoing and approval is pending.
Other camptothecins are under development, including 9-aminocamptothecin and 9-nitrocamptothecin (Wani et al., 1980; Kingsbury, 1991; Pantazis et al., 1992) and other analogs (Wang et al., 1994; Valenti et al., 1997; Zhao et al., 1997) . Some authors have described lipid formulations of camptothecin which display in vivo the capacitty to concentrate in the gastrointestinal tract (Sugarman, 1996) . It is important to realize that 9-nitro-camptothecin is converted by human cells to 9-amino-camptothecin, even by cells cultured in vitro (Pantazis et al., 1994b) . Until there are inhibitors of this metabolism, it cannot be determined if 9-nitro-camptothecin is active itself, or serves as a pro-drug for delivering the relatively unstable 9-amino-camptothecin to the target cells.
The camptothecins cure nude mice harboring xenografts from a variety of human cancers (Giovanella et al., 1989 (Giovanella et al., , 1991 Pantazis et al., 1994a; Friedman et al., 1994) . However, clinical studies demonstrated that continuous infusion and multiconsecutive day schedules were limited by severe neutropenia that occurred at dosages 3-15% of the murine MTD Kantarjian et al., 1993; Verweij et al., 1993; Dahut et al., 1994; Hochster et al., 1994; Pratt et al., 1994) , even with G-CSF support (Saltz et al., 1993; Slichenmyer et al., 1993) . These doses are well below the curative doses in the nude mouse models. The human MTD is 1.4 mg m −2 day −1 on a qdx5 schedule without cytokine support Saltz et al., 1993 , Verweij et al., 1993 , and the mouse LD10 on the same schedule is 14 mg m −2 day −1 . Obviously the full curative potential of these drugs will not be realized without the development of approaches, in addition to cytokine support, to compensate for the dose limiting neutropenia. The decreased drug tolerance of human compared to mouse is unlikely to be due to pharmacokinetic differences, since plasma clearance rate of topotecan is similar in humans and mice .
An important aspect of the pharmacology of the camptothecin compounds is the equilibrium between hydroxy acid (hydrolyzed A ring) and lactone forms, the latter being responsible for cytotoxicity . Mi and Burke have shown that 13-18% of total TPT exists in the lactone form at equilibrium regardless of the protein concentration or the species of origin of the plasma, and there are no differences between mouse and human in the plasma equilibrium levels of TPT lactone Mi, 1993, 1994; Mi and Burke, 1994a, b) . However, other members of the family do show dramatic inter-species differences in the percent lactone at equilibrium. For example, the equilibrium is shifted more toward the hydroxy acid of CAM by human serum albumin than by murine, and 9-amino-camptothecin shows large differences in percent lactone at equilibrium between dog (25%) and human (<0.5%) Mi, 1993, 1994; Mi and Burke 1994a, b) .
Nevertheless, the clinical success of the camptothecin series has established topoisomerase I as an important and commercially viable pharmacological target in cancer treatment. Thus, there is an active effort to develop additional topoisomerase I inhibitors with structures and properties distinct from the camptothecins, such as benzophenanthridine alkaloids (nitidine and fagaronine) (Wang LK, 1993) , coralyne and its analogues (Wang LK, 1996) , intoplicine (Abigerges et al., 1996) , Gl147211C (Besterman et al., 1996; Gerrits et al., 1996) , quinolines and quinoxalines (Deady et al., 1997) , benzimidazoles (Kim et al., 1996) , an ellipticine-distamycin hybrid (Riou et al., 1995) , and others (Funabashi et al., 1994; Gupta et al., 1995; Meikle et al., 1995; Boege et al., 1996; Cummings et al., 1996; Funayama et al., 1996; Makhey et al., 1996; Ray et al., 1996 Ray et al., , 1997 Rodriguez-Campos et al., 1996; Xie et al., 1996; Spicer et al., 1997) . This promising class of anticancer drugs also exhibits antiviral activity (Priel et al., 1991) .
Obviously, the complicated nature of the reaction catalyzed by topoisomerase I suggests several mechanisms by which it can be inhibited, and it seems likely that several mechanistic classes of topoisomerase inhibitors will emerge. This may be of some benefit clinically as acquired resistance to one mechanism via mutation may not necessarily confer cross-resistance to the other mechanisms.
Cytotoxicity of Topoisomerase I Inhibitors
Topoisomerase I inhibitors are drugs able to bind the cleavable complex Topo I-DNA resulting in single strand DNA breaks that in the presence of drug cannot be religated (Creemers et al., 1994) . Although the steps by which the formation of cleavable complex by camptothecin occurs is not fully clarified, it seems that camptothecin complexes at sites having a G at their 5 -DNA terminus and non-contiguous domains of Topo I with the consequent block of the resealing step of strand-passsing reaction (Hsiang, 1985; Jaxel et al., 1991; Rubin et al., 1994) . DNA cleavage pattern observed after denaturation shows wide variation in cleavege sites intensity and moreover the cleavages occurs at sites that were not detectably cleaved in the absence of drug (Perez-Stable et al., 1988) . Since cleavages should occur at sequences with similar twist angle variation it has been proposed that camptothecin produces alteration of the topo I cleavage pattern as a consequence of alteration of the enzyme's normal recognition of twist angle variations (Shen, 1990) . The cytotoxicity of camptothecins is cell cycle phase-specific, specifically in S-phase (Li et al., 1972) , and it has been calculated that a cell in S-phase is about 1000 times more sensitive to the effect of camptothecin than cells in G1 or G2 phase (Horwitz, 1975) . However, if the toxicity is measured as damage produced by camptothecin on DNA the result is very similar either in S-phase cells and in cells in G1-phase (Horwitz, 1973) . This apparent discrepancy suggests that the cause of cell death by camptothecin is probably due to the collision between the cleavage complex and the replication forks and that the entering in Sphase converts a reversible damage of DNA into a lethal lesion. This hypothesis of cell kill is also supported by studies on in vitro models with SV-40 virus replicating in cell free systems (Hsiang et al., 1989) even if it is also possible that a part of the lethal effects may be due to the stabilization of cleavable complexes in genomic regions essential for cell viability (Hsiang et al., 1989) .
The capacity of camptothecin and other topo I inhibitors to kill cells is considered a very interesting perspective for the treatment of tumors with elevated Topo I level or activity (Houghton et al., 1992; Bronstein et al., 1996) . The progressive knowledge that the mechanism of action of Camptothecin and its derivatives was directed against topo I allowed to better clarify some effects on cellular functions but does not explain completely the mechanism of cell killing. The inhibition of RNA synthesis is a reversible phenomenon probably due to the Camptothecin altered cleavable complex which blocks the elongation process by preventing the progression of RNA polymerase molecules along the transcription unit (Zhang, 1990) . If camptothecin is removed from cells the phenomenon reverses (probably because the topo I cleavable complex dissociates from the transcription unit) and RNA synthesis restarts.
Multiple Drug Resistance
Since for an antitumor drug, the selectivity of action is fundamental, many studies were directed to investigate the mechanisms by which cells become resistant to drug treatment (Clynes, 1993) . For drugs acting on topoisomerases it has been reported that irreversible damages occur with a higher frequency in cells containing high levels of these enzymes (that is the case of many tumoral cells) ( Van der Zee et al., 1991) . When a tumor cell population has a low content of topoisomerases it becomes refractory to the treatment and this type of resistance is called primary resistance. Different mechanisms of resistance have been characterized in many different experimental systems and currently they may be classified into three basic groups according to the mechanisms involved: drug transport (Endicott et al., 1989) , drug-target interaction (Beck, 1987) and drug detoxification (Deffie et al., 1988) .
The most important phenomenon of resistance made evident was the so called 'multiple drug resistance' (MDR) that is caused by the drug transportation made by a 'pump' system requiring energy and able to throw the drug out of the cell (Endicott et al., 1989; Roninson, 1992) . The best example of MDR is represented by a 170 kDa P-glycoprotein (P-gp), a member of a family of proteins acting as membrane carriers of different chemical compounds such as sugar, ions, hormons and proteins and by multi-resistance associated proteins of 190 kDa (MRP) (these systems have been reviewed by Clynes et al., 1990; Gerrmann, 1996; Loe, 1996) . The P-glycoprotein is present in normal tissues in which it protects the cells against toxic compounds providing an important factor of selectivity (Fojo et al., 1987) that during chemotherapy protects normal cells whereas it does not defend neoplastic cells which do not contain P-gp. Unfortunately, this selectivity is lost when tumoral cells express Pglycoprotein by acquiring MDR phenotype and worst when the P-gp is associated with the expression of 'ras' and 'p53' oncogenes then an acceleration of tumor growth occurs (Chin et al., 1992) . P-glycoprotein is encoded by MDR-1 gene and may be the result both of a gene expression as well as of a gene amplification process. The main part of the studies (performed on topoisomerases II poisons) pointed out that MDR cells are very resistant to Vinca alkaloids such as vincristine or vinblastine, moderately resistant to doxorubicin, etoposide and teniposide while maintaining a relative sensitivity to amsacrine (Qian et al., 1990; Baguley et al., 1990) . However, it must be considered that some MDR mechanisms are not associated with increased expression of P-glycoprotein although modifications of the drug transport are involved. As observed by Scheper et al., 1993 , several p-glycoprotein-negative MDR cell lines overexpressed a Mr = 110 000 protein (p110) termed lung resistance related protein (LRP) (see the recent review of Izquierdo et al., 1996) which may have a physiological function in several normal tissues, possibly involving a transport mechanism. Many in vitro cell lines with increased expression of P-glycoprotein and resistant to drug inhibition were obtained and also many spontaneous human tumors were described to become MDR. For these reasons several 'in vitro' methods have been developed in order to check the presence of MDR in tumor cells. Some methods are based on the direct detection of Pgp in histological sections of tumoral tissues or cells by using specific monoclonal antibodies labelled with fluorescein (Thiebaut et al., 1987) . Other ones check the MDR-1 gene expression by DNA-RNA hybridation techniques (Fojo et al., 1987) . Analytic methods based on the cytometry were developed by exploiting the capacity of MDR cells to throw out from the cytoplasm different fluorochromes (Nooter et al., 1991; Ludescher et al., 1991) . Also the polymerase chain reaction (PCR) was recently used to analyze the expression of mdr1 gene in tumor sample from breast cancer patients (Yang et al., 1993) . It is important to remember a last method which has the advantage of detecting other MDR mechanisms unrelated to the expression of P-gp. This aim is obtained by cultur-ing tumor cells in the presence of two different drugs having similar structure but different susceptibility to MDR mediated by P-gp. Thus, the ratios between the IC50 values calculated for the two drugs may be considered as an index of MDR (Baguley et al., 1990) .
Drug Resistance to Topopoisomerase I Inhibitors
As mentioned above the number of DNA strand breaks induced by topoisomerase inhibitors is dependent on the number of molecules of enzymes in the cells. For this reason, the most simple mechanism of resistance to drugs acting against topoisomerases is consistent with the decrease of cell content or subcellular redistribution of these enzymes (Kanzawa et al., 1990; Danks et al., 1996; Buckwalter et al., 1996) . This is the case with the 'cyclic' changes of resistance to topoisomerase-inhibitors which is directly related to the variation of the intracellular content of these enzymes along the cell cycle (Heck et al., 1988; Barronco, 1984) . During the Go-G1 phase, many enzymes utilized for DNA duplication process are degraded while their new synthesis starts just before the new DNA replication phase begins (S-phase) (Andrews, 1992) . This phenomenon of resistance is called 'cytokinetic resistance' and it seems to play an important role in the protection of normal tissues from toxics ingested with the food or administered during chemotherapy. This type of resistance may be the most probable mechanism which determines the insensitivity of many solid tumors to the chemotherapy. Thus, the quantitative reduction of topo I content seems to be the most frequently occurring event in the development of camptothecin resistance . A development of resistance to inhibitors of topo I occurring by down-regulation of the target enzyme, thus reducing the production of lethal enzyme-mediated DNA damages has also been suggested (Eng et al., 1990) . However, according to some authors, the resistance to topoisomerase inhibitors is not a cycle specific resistance but rather a combination between a decreased quantity of topoisomerases and a diminished direct sensitivity of the enzymes to the drug Kjeldsen et al., 1988) . This last mechanism producing resistance was well documented for topo II and was defined at-MDR (Altered Topo-MDR) Snow et al., 1991) .
For topo I the data is not so homogeneous although topo I alterations have been proposed to produce acquired resistance to camptothecin in mammalian cells. Some cells have been characterized which exibited altered topo I Gupta et al., 1988) and in some mutants it was even shown that the activity of Topo I extracted from cells resistant to camptothecin was three times as active than topo I from wild type cells (Lefevre et al., 1991) . Studies with a mutated camptothecin resistant form of topoisomerase I (TOPO I-K5) indicated a higher cleavage/religation activity of topo I-K5 as a result of improved DNA binding and a concomitant shift in the equilibrium between cleavage and religation towards the religation step (Gromova et al., 1993) . Also Tanizawa et al. (1992) observed that resistance to camptothecin was associated with a marked reduction of drug-induced DNA strand breaks concluding that camptothecin resistance in DC3f/C10 cells is due to the qualitative alteration of DNA topo I. Ishimi et al. (1991) isolated a topo I mutant conferring camptothecin resistance but not able to affect its functions involved in cellular DNA replication. However, while topo II poisons are in general sensitive to MDR1 mediated resistance, the topo I poisons such as camptothecin and its derivatives appear completely insensitive to MDR1 overexpression (Liu, 1990) . In fact, alterations of DNA topo I are unrelated to the acquisition of MDR characters (Oguro et al., 1990) but neither does the P-glycoprotein associated with MDR phenotype modify the sensitivity to camptothecin and its derivatives (Giovanella et al., 1991) . Moreover, MDR1 overexpression was shown to have little effect on camptothecin cytotoxicity and the capacity of this drug to overcame MDR1 mediate resistance is most likely due to its unimpaired accumulation in MDR-1 cells (Chen et al., 1991) . Only very recent experimental evidence points out that MDR cells can be resistant also to camptothecin and its derivatives and that P-gp overexpression diminishes accumulation and toxicity of topo I poisons in hamster and human cells Yang et al., 1995) Recently also the possible role of p53 has been investigated (Shimizu et al., 1996) .
For purposes of this review, drug resistance to camptothecins has been organized around four questions (Pessina, 1993; Prost, 1995) . First, does resistance to camptothecins induce cross-resistance to other drug classes? Second, does resistance to commonly used chemotherapeutic agents induce crossresistance to camptothecins? Third, what are the mechanisms of resistance that can reduce chemosensitivity of tumor cells during therapy with camptothecins? Fourth, are there any known mechanisms of multi-drug resistance that do not affect chemosen-sitivity to camptothecins?
There is only weak collateral chemosensitivity between topotecan and other agents, and resistance to camptothecins does not ususally confer crossresistance to topoisomerase II inhibitors (e.g., VP-16), microtubule-targeted drugs (e.g., Taxol), or alkylating agents (Ferguson et al., 1988; Gupta et al., 1988; Eng et al., 1990; Pantazis et al., 1994c; Supino et al., 1996; Jensen et al., 1997) . Furthermore, a dominant negative p53 genotype that confers cross-resistance to doxorubicin, cisplatin, and Ara-C does not affect sensitivity to camptothecin or paclitaxel (Vasey et al., 1996) . Human tumor cell lines resistance to topoisomerase I poisons do not exhibit collateral chemosensitivity between gemacitabine and ara-C (Jensen et al., 1997) . Consistent with infrequent cross-resistance patterns, prior myelosuppressive chemotherapy does not alter subsequent camptothecin-induced myelotoxicity (EORTC, 1992) .
However, induction of camptothecin resistance under laboratory conditions has been associated with cross-resistance to cisplatin (Fujimori et al., 1996) , and cisplatin and topotecan resistance can be related (Niimi et al., 1992; Jensen et al., 1997) . These findings contrast with the synergistic activity of co-exposure to cisplatin and SN-38 metabolite of CPT-11 (Fukuda et al., 1996) .
There are many mechanisms that could contribute to the resistance of malignancies to camptothecins. Camptothecin resistance can be linked to alterations in topoisomerase I structure Gupta et al., 1988; Jaxel et al., 1989; Lefevre et al., 1991; Ishimi et al., 1991; Beck and Danks, 1991; Kubota et al., 1992; Knab et al., 1993; Tanizawa et al., 1993; Carrigan et al., 1997) . This mechanism has been reviewed in detail Nitiss and Beck, 1996; Rothenberg, 1997) .
Increased activity of drug efflux transport systems which actively pump natural products out of the cell and minimize intracellular accumulation could be another mechanism of resistance. The best know efflux system in the context of chemotherapy is the mdr-1 gene product, also known as P170 or P-glycoprotein. Some camptothecins appear to be substrates of P170 whereas others are not, and the presence of ionized functional groups on the camptothecin ring system may be required for interaction with the P170 system Giovanella et al., 1991; Chen et al., 1991; Nakatsu et al., 1997; Hoki et al., 1997) . Interestingly, topotecan is a P170 substrate whereas 9-amino-camptothecin is not Hoki et al., 1997) . To our knowledge, the role of the MRP system in camptothecin resistance has not been evaluated experimentally.
An ovarian carcinoma line resistant to cisplatin exhibited cross-resistance to irinotecan in spite of similar levels of intracellular drug accumulation and topoisomerase I activities. However, multiple mechanisms appeared to contribute to the resistance to CPT-11, including glutathione-dependent pathways and dimished intracellular conversion of CPT-11 to its active metabolite, SN-38 (Niimi et al., 1992) .
Mutants can be produced that are resistant to camptothecin at the cellular level, even though the isolated topoisomerase I shows no change in sensitivity to camptothecin, if there is increased repair of topoisomerase I-dependent lesions in the DNA (Fujimori et al., 1996) . However, these mutants were isolated by selection in camptothecin after treatment with the mutagen MMS, and may not be clinically relevant.
One final observation about cellular resistance to camptothecins should influence the development of new generation camptothecins. There are large inter-species differences in tolerated doses, and rodents can tolerated significantly higher doses of the camptothecins than the human. Differential sensitivity across species can be reproduced in vitro using direct drug exposure of hematopoietic progenitors in the bone marrow of the various species (Erickson-Miller et al., 1997) . Because of its similar pharmacokinetics in mice and humans , topotecan is the best camptothecin to study in vitro. Its LD10:MTD ratio of 10 and its ratio of peak plasma concentrations of 22 are replicated in vitro by the sensitivity of neutrophil progenitors from mouse and human (Erickson-Miller et al., 1997) . Thus, there is increased drug resistance even in normal proliferating rodent cells relative to their human counterparts. The mechanism responsible for this differential tolerance has not been identified, but the findings suggest pharmacodynamic differences that result in relative drug resistance at the cellular level. It will be interesting to discover if differential tolerance is a feature of any drug that inhibits topoisomerase I, or whether it pertains specifically to the camptothecin family of inhibitors or their specific molecular target on the enzyme. It will be important to identify the mechanism because it is responsible in large part for the dimished efficacy of camptothecins against human tumors in patients compared to mouse models (Erickson-Miller et al., 1997) . All of these mechanisms of drug resistance reside at the cellular or sub-cellular level. However, tumors could acquire 'resistance' to camptothecins via physiological mechanisms that lie above the cellular level (reviewed in Pessina, 1993) . Since the expression of topoisomerase I is regulated during cell cycle progression, tumors with low growth fractions and high proportions of quiescent (G o ) progenitor cells and stem cells would be refractory to camptothecin therapy, assuming the regulation of the enzyme's expression and function are similar in tumor cells and their normal counterparts. In addition, there could be significant clinical implications to the findings (Beidler and Cheng, 1995; Murren et al., 1996; Taniguchi et al., 1996) that camptothecin treatment down-regulates topoisomerase I levels.
There are some interesting clinical observations that suggest another mechanisms of 'physiological resistance' to camptothecins. CPT-11 is a pro-drug that is metabolized to an active metabolite called SN-38, and this metabolite is further metabolized to a glucuronide conjugate that appears in the plasma of patients treated with CPT-11 (Gupta et al., 1994) . Patients exhibiting the lowest extent of metabolism of SN-38 to the glucuronide experience the most severe toxicity (diarrhea), which suggests that drug tolerance in individual patients is determined by how much unconjugated SN-38 gains access to the bile to cause cytotoxicity to the intestinal mucosa (Gupta et al., 1994; Ikuno et al., 1995) . In terms of 'drug resistance', these findings suggest that patients with low glucuronyl transferase activity will tolerate lower dose of CPT-11 than other patients. Assuming there is not any difference in tumor sensitivity in these patients, the lower tolerated doses of CPT-11 will result in less efficacious treatment in this patient subpopulation, and the tumors would appear to be 'resistant'. However, the mechanism of tumor resistance is pharmacokinetic in nature, rather than cellular.
Future Perspectives
It seems likely that several factors will continue to drive the development of topoisomerase I inhibitors. In addition to the obvious commercial success of this class of drugs, the relative lack of drug crossresistance to other classes of antineoplastic agents and its activity in otherwise refractory disease are significant findings. The complex mechanism of topoisomerase I catalysis suggests multiple pharmacological strategies, and new enzyme inhibitors are under development. Furthermore, it may be possible to design topoisomerase I poisons which are toxic only to cells that have mutations in topoisomerase I that confer resistance to other mechanistic classes. Since some camptothecins are substrates of xenobiotic efflux pumps whereas others are not, it will be important to elucidate the structural features that make the difference between the two. A final point is for the reader to be aware of the fact that a topoisomerase I has been isolated from mammalian mitochondria (Lin and Castora, 1995) .
In addition to the obvious cellular and molecular mechanisms (drug efflux pumps, DNA repair, etc.) that contribute to resistance to camptothecins, there are pharmacological mechanisms that lie above the cellular level that are not detectable in in vitro assays of antitumor activity. For some camptothecins, these mechanisms determine to a large degree whether a tumor appears 'resistant'. Especially when camptothecins are administered with other medications that can decrease drug tolerance (e.g., inhibit glucuronidation) and therefore decrease delivered dose, these factors need to be considered when drawing conclusions about resistance of tumors to therapy. Apparently, it is not sufficient to analyze only the subcellular mechanisms to understand why a given patient's tumor fails to respond to certain camptothecins. It is also important to incorporate the inter-species differences in percent lactone when designing and extrapolating in vitro assays of camptothecins to the in vivo setting (Erickson-Miller et al., 1997) . In vitro evaluations will be most meaningful when they include human plasma (or serum albumin) for human cell assays and murine for murine cell assays to accommodate these species differences in percent lactone at equilibrium. Topotecan is a notable exception and does not show such inter-species differences (Mi and Burke, 1994b) .
One serious limitation to the clinical promise of camptothecins is the unfortunate lack of tolerance of the drugs in human patients. The 10-fold or greater sensitivity of human than murine neutrophil progenitors will have to be overcome to achieve the doses in patients that cure mice with human tumor xenografts. Since the mechansim(s) responsible for this large inter-species difference in drug tolerance might be difficult to identify, it may prove difficult to increase human drug tolerance to the level of the mouse via the use of cytoprotectants like amifostine or by transgenic modification of hematopoietic stem cells. It may be more productive to return to preclinical development and identify myelosuppressive camptothecins that are still curative in the human tumor xenograft models yet show equal potency between mouse and human neutrophil progenitors. Another related issue of importance is to find out whether topoisomerase I plays a more critical role in human than murine hematopoiesis. It will be important to identify the mechanistic classes of topoisomerase I inhibitors that do NOT show inter-species differences in drug tolerance and have a chance at showing the same antitumor efficacy in patients as in xenograft models.
Regardless, topoisomerase I represents a novel and distinct molecular target for cancer chemotherapy, and increased understanding of the cellular and supracellular mechanisms that generate refractory disease will be valuable for the optimal development of this drug class. Although this knowledge base is apparently in its infancy, several issues have already been identified that may be unique to camptothecins or generally topoisomerase I poisons.
